Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.

Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, Hoogstraten C, van Liempt E, Zwaginga JJ, de Wreede LC, Meij P, Vossen ACTM, Danhof S, Einsele H, Schaafsma MR, Veelken H, Halkes CJM, Jedema I, Falkenburg JHF.

Leukemia. 2019 Oct 17. doi: 10.1038/s41375-019-0600-z. [Epub ahead of print]

PMID:
31624377
2.

New Insights Into the Kinetics and Variability of Egg Excretion in Controlled Human Hookworm Infections.

Hoogerwerf MA, Coffeng LE, Brienen EAT, Janse JJ, Langenberg MCC, Kruize YCM, Gootjes C, Manurung MD, Dekker M, Becker L, Erkens MAA, van der Beek MT, Ganesh MS, Feijt C, Winkel BMF, Westra IM, Meij P, Loukas A, Visser LG, de Vlas SJ, Yazdanbakhsh M, van Lieshout L, Roestenberg M.

J Infect Dis. 2019 Aug 9;220(6):1044-1048. doi: 10.1093/infdis/jiz218.

PMID:
31077279
3.

Establishing the Production of Male Schistosoma mansoni Cercariae for a Controlled Human Infection Model.

Janse JJ, Langenberg MCC, Kos-Van Oosterhoud J, Ozir-Fazalalikhan A, Brienen EAT, Winkel BMF, Erkens MAA, van der Beek MT, van Lieshout L, Smits HH, Webster BL, Zandvliet ML, Verbeek R, Westra IM, Meij P, Visser LG, van Diepen A, Hokke CH, Yazdanbakhsh M, Roestenberg M.

J Infect Dis. 2018 Aug 24;218(7):1142-1146. doi: 10.1093/infdis/jiy275.

PMID:
29905805
4.

Label-Free, Flow-Imaging Methods for Determination of Cell Concentration and Viability.

Sediq AS, Klem R, Nejadnik MR, Meij P, Jiskoot W.

Pharm Res. 2018 May 30;35(8):150. doi: 10.1007/s11095-018-2422-5.

5.

A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.

Coppens DGM, de Wilde S, Guchelaar HJ, De Bruin ML, Leufkens HGM, Meij P, Hoekman J.

Cytotherapy. 2018 Jun;20(6):769-778. doi: 10.1016/j.jcyt.2018.03.038. Epub 2018 May 2.

PMID:
29730080
6.

EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.

de Wilde S, Coppens DGM, Hoekman J, de Bruin ML, Leufkens HGM, Guchelaar HJ, Meij P.

Drug Discov Today. 2018 Jul;23(7):1328-1333. doi: 10.1016/j.drudis.2018.03.008. Epub 2018 Mar 21. Review.

7.

Understanding clinical development of chimeric antigen receptor T cell therapies.

de Wilde S, Guchelaar HJ, Zandvliet ML, Meij P.

Cytotherapy. 2017 Jun;19(6):703-709. doi: 10.1016/j.jcyt.2017.03.070. Epub 2017 Apr 19. Review.

PMID:
28433515
8.

Clinical development of gene- and cell-based therapies: overview of the European landscape.

de Wilde S, Guchelaar HJ, Zandvliet ML, Meij P.

Mol Ther Methods Clin Dev. 2016 Nov 30;3:16073. eCollection 2016.

9.

Development of cell therapy medicinal products by academic institutes.

de Wilde S, Guchelaar HJ, Herberts C, Lowdell M, Hildebrandt M, Zandvliet M, Meij P.

Drug Discov Today. 2016 Aug;21(8):1206-12. doi: 10.1016/j.drudis.2016.04.016. Epub 2016 Apr 23.

PMID:
27117349
10.

Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.

de Wilde S, Veltrop-Duits L, Hoozemans-Strik M, Ras T, Blom-Veenman J, Guchelaar HJ, Zandvliet M, Meij P.

Cytotherapy. 2016 Jun;18(6):797-805. doi: 10.1016/j.jcyt.2016.02.010. Epub 2016 Apr 5.

PMID:
27068764
11.

Successful RAG1-SCID gene therapy depends on the level of RAG1 expression.

Pike-Overzet K, Baum C, Bredius RG, Cavazzana M, Driessen GJ, Fibbe WE, Gaspar HB, Hoeben RC, Lagresle-Peyrou C, Lankester A, Meij P, Schambach A, Thrasher A, Van Dongen JJ, Zwaginga JJ, Staal FJ.

J Allergy Clin Immunol. 2014 Jul;134(1):242-3. doi: 10.1016/j.jaci.2014.04.033. Epub 2014 Jun 26. No abstract available.

PMID:
25117803
12.

A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells.

van Loenen MM, de Boer R, van Liempt E, Meij P, Jedema I, Falkenburg JH, Heemskerk MH.

Haematologica. 2014 Apr;99(4):759-68. doi: 10.3324/haematol.2013.093690. Epub 2013 Dec 13.

13.

Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines.

Meij P, Jedema I, Zandvliet ML, van der Heiden PL, van de Meent M, van Egmond HM, van Liempt E, Hoogstraten C, Kruithof S, Veld S, Marijt EW, von dem Borne PA, Lankester AC, Halkes CJ, Falkenburg JH.

J Immunother. 2012 Oct;35(8):621-8.

PMID:
22996368
14.

Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study.

Meij P, Jedema I, van der Hoorn MA, Bongaerts R, Cox L, Wafelman AR, Marijt EW, Willemze R, Falkenburg JH.

Haematologica. 2012 Aug;97(8):1205-8. doi: 10.3324/haematol.2011.053371. Epub 2012 Apr 17.

15.

Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides.

Zandvliet ML, Kester MG, van Liempt E, de Ru AH, van Veelen PA, Griffioen M, Guchelaar HJ, Falkenburg JH, Meij P.

J Immunother. 2012 Feb-Mar;35(2):142-53. doi: 10.1097/CJI.0b013e318243f1ed.

PMID:
22306902
16.

Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.

Lugthart G, Albon SJ, Ricciardelli I, Kester MG, Meij P, Lankester AC, Amrolia PJ.

J Immunother. 2012 Jan;35(1):42-53. doi: 10.1097/CJI.0b013e31823569e2.

PMID:
22130159
17.

Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.

Zandvliet ML, van Liempt E, Jedema I, Kruithof S, Kester MG, Guchelaar HJ, Falkenburg JH, Meij P.

J Immunother. 2011 Apr;34(3):307-19. doi: 10.1097/CJI.0b013e318213cb90.

PMID:
21389867
18.

Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection.

Zandvliet ML, Falkenburg JH, van Liempt E, Veltrop-Duits LA, Lankester AC, Kalpoe JS, Kester MG, van der Steen DM, van Tol MJ, Willemze R, Guchelaar HJ, Schilham MW, Meij P.

Haematologica. 2010 Nov;95(11):1943-51. doi: 10.3324/haematol.2010.022947. Epub 2010 Jun 18.

19.

Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.

Zandvliet ML, van Liempt E, Jedema I, Veltrop-Duits LA, Willemze R, Guchelaar HJ, Falkenburg JH, Meij P.

Cytotherapy. 2010 Nov;12(7):933-44. doi: 10.3109/14653240903505822.

PMID:
20078388
20.

Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy.

Zandvliet ML, Falkenburg JH, Jedema I, Willemze R, Guchelaar HJ, Meij P.

J Immunother. 2009 Jun;32(5):513-23. doi: 10.1097/CJI.0b013e3181a2712c.

PMID:
19609244
21.

Dissection of the CMV specific T-cell response is required for optimized cardiac transplant monitoring.

Kirchner A, Hoffmeister B, Cherepnev-G G, Fuhrmann S, Streitz M, Lachmann R, Bunde T, Meij P, Schönemann C, Hetzer R, Lehmkuhl HB, Volkmer-Engert R, Volk HD, Gratama JW, Kern F.

J Med Virol. 2008 Sep;80(9):1604-14. doi: 10.1002/jmv.21229.

PMID:
18649330
22.

Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay.

Jedema I, Meij P, Steeneveld E, Hoogendoorn M, Nijmeijer BA, van de Meent M, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):636-43.

23.

Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease.

Meij P, van Esser JW, Niesters HG, van Baarle D, Miedema F, Blake N, Rickinson AB, Leiner I, Pamer E, Lowenberg B, Cornelissen JJ, Gratama JW.

Blood. 2003 Jun 1;101(11):4290-7. Epub 2003 Feb 6.

PMID:
12576337
24.

Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease.

Meij P, Vervoort MB, Bloemena E, Schouten TE, Schwartz C, Grufferman S, Ambinder RF, Middeldorp JM.

J Med Virol. 2002 Nov;68(3):370-7.

PMID:
12226824
25.

Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2.

Meij P, Leen A, Rickinson AB, Verkoeijen S, Vervoort MB, Bloemena E, Middeldorp JM.

Int J Cancer. 2002 May 1;99(1):93-9.

26.

Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.

Leen A, Meij P, Redchenko I, Middeldorp J, Bloemena E, Rickinson A, Blake N.

J Virol. 2001 Sep;75(18):8649-59.

27.

Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.

Meij P, Bloemena E, Palmen N, Brink A, Vervoort MB, Meijer CJ, Middeldorp JM.

Cell Immunol. 2001 Feb 25;208(1):25-33.

PMID:
11277616
28.

Production monitoring and purification of EBV encoded latent membrane protein 1 expressed and secreted by recombinant baculovirus infected insect cells.

Meij P, Vervoort MB, Meijer CJ, Bloemena E, Middeldorp JM.

J Virol Methods. 2000 Nov;90(2):193-204.

PMID:
11064119
29.

Bioreactor-scale production and one-step purification of Epstein-Barr nuclear antigen 1 expressed in baculovirus-infected insect cells.

Meij P, Vervoort MB, de Gooijer K, Bloemena E, Meijer CJ, Middeldorp JM.

Protein Expr Purif. 2000 Nov;20(2):324-33.

PMID:
11049756
30.

Direct immunosuppressive effects of EBV-encoded latent membrane protein 1.

Dukers DF, Meij P, Vervoort MB, Vos W, Scheper RJ, Meijer CJ, Bloemena E, Middeldorp JM.

J Immunol. 2000 Jul 15;165(2):663-70.

31.

Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.

Meij P, Vervoort MB, Aarbiou J, van Dissel P, Brink A, Bloemena E, Meijer CJ, Middeldorp JM.

J Infect Dis. 1999 May;179(5):1108-15.

PMID:
10191211

Supplemental Content

Support Center